Vilma Lukaševičienė

Vilma Lukaševičienė

Auto-generated profile, based on publicly available information

Vilma Lukaševičienė

Faculty of Medicine, Institute of Health Sciences, Centre for Health Ethics, Law and History, Vilnius University, Vilnius, Lithuania

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2020 in Journal of Medical Ethics
Verified
Journal Article
Closed access
PDF file
VLVilma Lukaseviciene
Vilma Lukaseviciene
JHJoerg Hasford
Joerg Hasford
DLDirk Lanzerath
Dirk Lanzerath
EGEugenijus Gefenas
Eugenijus Gefenas
The upcoming Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use (Regulation), which will replace the current Clinical Trial Directive at the end of 2021, has triggered a significant reform of research ethics committee systems in Europe. Changes related to ethics review of clinical trials in the EU were considered to be essential to create a more favourable environment to conduct clinical trials in the EU. The concern is, however, that the role of the research ethics committees will weaken in at least some of the Member States because the new Regulation allows narrowing down the scope of ethics review as compared with the currently valid Clinical Trial Directive. Although the new Regulation may lead to faster approval procedures for clinical trials, which is especially relevant in the context of pandemics, high-quality ethics reviews integrating methodological aspects of a clinical trial should nevertheless be ensured. To maintain high research ethics standards as well as to foster measures to mitigate potential negative consequences of the reform, it is therefore of vital importance to start debating and sharing the reflections about the potential consequences of these transformations and trends as soon as possible.

10 January 2026 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
VLVilma Lukaševičienė
Vilma Lukaševičienė
Eugenijus GefenasEugenijus Gefenas
Eugenijus Gefenas
Background: the COVID-19 pandemic posed unprecedented challenges to global research ethics governance. In response to the urgent need for rapid scientific data, ethics review processes were accelerated, informed consent procedures adapted, and new research methods introduced. These changes were guided by the proliferation of research ethics guidelines issued by national, regional and international bodies. However, there has been limited systematic analysis of how these guidelines addressed key ethical challenges during the pandemic and shaped future ethical frameworks. This study aims to map the global network of pandemic related research guidelines, to analyze how they addressed the main pandemic specific ethical challenges. Methods: We conducted a systematic search of published research ethics and regulatory guidelines developed in response to the COVID-19 pandemic between 2020 and 2022. We applied a mixed methods approach: citation network analysis was used to visualize interconnections between guidelines and identify influential sources, and a thematic analysis was used to examine how guidelines addressed specific ethical issues. Results: the citation network analysis revealed a globally interconnected ethical framework with the WHO outbreak guidelines (2016) and CIOMS guidelines (2016) emerging as central references. Thematic analysis identified eight recurring ethical themes: research prioritization, research ethics oversight, inclusion of vulnerable populations, balancing risks and benefits, modifications of informed consent, data sharing and transparency, collaboration and preparedness, and public engagement. Guidelines encouraged procedural flexibilities (e.g., expedited reviews, e-consent) but also emphasized the need to maintain ethical rigor and scientific integrity. Tensions between speed and scrutiny, centralization and local context, public health goals and individual protection were recurring concerns. Integration of public health ethics, research integrity, and human rights frameworks emerged as a defining feature of most guidelines. Conclusions: COVID-19 catalyzed a shift toward more integrated and adaptive research ethics frameworks that combine individual protection and collective public health goals. These shifts are being reflected in recent updates of major ethics instruments such as the Declaration of Helsinki and new policy initiatives such as the European Health Data Space Regulation. However, gaps remain in harmonization, implementation, and preparedness planning. Continuous efforts are needed to harmonize ethics guidance, support research ethics committees in crisis contexts, and integrate preparedness planning into global research ethics governance.

21 January 2026 in NanoEthics
Verified
Journal Article
Open access
PDF file
VLVilma Lukaševičienė
Vilma Lukaševičienė
VAVygintas Aliukonis
Vygintas Aliukonis
Eugenijus GefenasEugenijus Gefenas
Eugenijus Gefenas
JLJūratė Lekstutienė
Jūratė Lekstutienė
MLMiltos Ladikas
Miltos Ladikas
DPDaniela Proske
Daniela Proske
Research on emerging technologies such as AI-driven health interventions, extended reality (XR) systems, biobanks, and genome editing poses novel ethical challenges that traditional ethics governance models struggle to address. This article explores various models of research ethics governance within the European Union (EU) context, starting from traditional one-time research ethics committee (REC) reviews, REC review with post-approval monitoring, as well as alternative models such as ethics self-assessment, and ethics-by-design approaches. Based on literature analysis and a survey of European research ethics experts, the study identifies prevalent models of research ethics oversight, research ethics expert perceptions of their sufficiency, and challenges such as insufficient technical and ethics expertise, lack of specific guidelines, and unclear boundaries of REC responsibilities. Findings also indicate that traditional REC reviews remain dominant but have limitations in effectively managing rapidly evolving technologies. Research ethics experts highlighted the feasibility of continuous oversight mechanisms to better integrate ethical reflection throughout the research lifecycle. The article concludes by recommending a shift towards proportional, risk-based oversight, development of clearer, technology-specific guidelines, enhanced REC training, and improved harmonization across EU ethics governance systems to address current gaps.

17 November 2026 in Health Research Policy and Systems
Verified
Journal Article
Open access
VAVygintas Aliukonis
Vygintas Aliukonis
VLVilma Lukaševičienė
Vilma Lukaševičienė
MPMargarita Poškutė
Margarita Poškutė
Eugenijus GefenasEugenijus Gefenas
Eugenijus Gefenas

29 September 2026 in Journal of Empirical Research on Human Research Ethics
Verified
Journal Article
Closed access
CSCarly Jean Seedall
Carly Jean Seedall
JLJūratė Lekstutienė
Jūratė Lekstutienė
VLVilma Lukaševičienė
Vilma Lukaševičienė
AGAgnė Girkontaitė
Agnė Girkontaitė
LTLisa Tambornino
Lisa Tambornino
Eugenijus GefenasEugenijus Gefenas
Eugenijus Gefenas
Research ethics committees (RECs) help uphold ethical research, but little is known about how their funding affects their capacity, especially in crises. Via survey data from 324 REC representatives in 80 countries, we examine funding sources, perceived compensation adequacy, and operational challenges during the COVID-19 pandemic. About one-fifth reported having no funding for operations or compensation, and only around one-third viewed their compensation as adequate. Funding constraints were more pronounced in low- and middle-income countries and may be associated with greater reported challenges. Our findings suggest that REC resilience during crises depends on stable support, especially from policymakers and institutional leaders.